Jazz Pharmaceuticals (JAZZ) fundamentals: P/E, valuation, undervalued?
Jazz Pharmaceuticals · Health Care · ref. ETF XLV · price $210.39
In short — Jazz Pharmaceuticals trades at 14.4× earnings (P/E), 8.1× forward, with a net margin of 20.4 % and revenue growth of +16 %. Read: Cheap for the growth (P/E 8 for ~16% growth (PEG 0.5)).
Is Jazz Pharmaceuticals stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$210.39+57.2% over range
Oct 14, 25low $131.16 · high $261.62Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
94% recommend buying · 17 analysts
Valuation : Cheap for the growth — P/E 8 for ~16% growth (PEG 0.5)
Valuation
14.4
P/E (price/earnings)
8.1
Forward P/E
—
PEG
2.8
Price/book (P/B)
$13.7B
Market cap
14.59
EPS
Profitability & growth
20.4 %
Net margin
+16 %
Revenue growth
—
Earnings growth
$4.4B
Total debt
Jazz Pharmaceuticals income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $3.7B | $-224M | -6.1 % |
| 2023 | $3.8B | $415M | 10.8 % |
| 2024 | $4.1B | $560M | 13.8 % |
| 2025 | $4.3B | $-356M | -8.3 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Jazz Pharmaceuticals's P/E and is the stock undervalued? What's a good P/E?
Jazz Pharmaceuticals's P/E is 14.4 (forward 8.1). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Jazz Pharmaceuticals profitable?
Jazz Pharmaceuticals has a net margin of 20.4 % (EPS 14.59). The company is profitable.
Is JAZZ stock expensive?
Our read: "Cheap for the growth" — P/E 8 for ~16% growth (PEG 0.5). Cross-check with growth and sector.
💬 A question about Jazz Pharmaceuticals? The JPI assistant answers using our backtest data.
Keep exploring Jazz Pharmaceuticals